title: Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?
abstract: Compelling evidence indicates Type I CD20 immunotherapeutic mAbs promote targeted tumor cell elimination exclusively via immune effector functions, which can be exhausted/saturated. mAb dosing paradigms should therefore take into account the capacity of these cytotoxic mechanisms, leading to the conclusion that lower doses, given frequently, may be far more effective.
authors.affiliation: Department of Biochemistry and Molecular Genetics; University of Virginia School of Medicine; Charlottesville, VA USA.
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Lindorfer
authors.forename: Adrian
authors.initials: A
authors.lastname: Wiestner
authors.forename: Clive S
authors.initials: CS
authors.lastname: Zent
authors.forename: Ronald P
authors.initials: RP
authors.lastname: Taylor